全文获取类型
收费全文 | 670篇 |
免费 | 36篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 42篇 |
妇产科学 | 1篇 |
基础医学 | 193篇 |
口腔科学 | 7篇 |
临床医学 | 98篇 |
内科学 | 151篇 |
皮肤病学 | 35篇 |
神经病学 | 9篇 |
特种医学 | 5篇 |
外科学 | 65篇 |
综合类 | 31篇 |
预防医学 | 7篇 |
眼科学 | 11篇 |
药学 | 14篇 |
中国医学 | 3篇 |
肿瘤学 | 42篇 |
出版年
2023年 | 11篇 |
2022年 | 8篇 |
2021年 | 19篇 |
2020年 | 23篇 |
2019年 | 39篇 |
2018年 | 61篇 |
2017年 | 26篇 |
2016年 | 6篇 |
2015年 | 15篇 |
2014年 | 35篇 |
2013年 | 37篇 |
2012年 | 14篇 |
2011年 | 43篇 |
2010年 | 22篇 |
2009年 | 23篇 |
2008年 | 31篇 |
2007年 | 36篇 |
2006年 | 30篇 |
2005年 | 32篇 |
2004年 | 30篇 |
2003年 | 29篇 |
2002年 | 21篇 |
2001年 | 24篇 |
2000年 | 17篇 |
1999年 | 13篇 |
1998年 | 5篇 |
1997年 | 13篇 |
1996年 | 6篇 |
1995年 | 9篇 |
1994年 | 5篇 |
1993年 | 9篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
排序方式: 共有715条查询结果,搜索用时 15 毫秒
1.
Tetsuo Mitsui Naoto Fujita Yuhki Koga Reiji Fukano Tomoo Osumi Asahito Hama Katsuyoshi Koh Harumi Kakuda Masami Inoue Takahiro Fukuda Hiromasa Yabe Junko Takita Akira Shimada Yoshiko Hashii Atsushi Sato Yoshiko Atsuta Yoshinobu Kanda Junji Suzumiya Ryoji Kobayashi 《Pediatric blood & cancer》2020,67(4)
2.
3.
《Best Practice & Research: Clinical Haematology》2022,35(4):101400
Acute GVHD occurs in nearly 50% of patients receiving hematopoietic cell transplantation (HCT), and is the major driver of mortality. However, progress in the development of new acute GVHD therapeutics has been slow, in part due to heterogeneity in acute GVHD data collection and interpretation among centers. Herein, we first describe the methods used by the Mount Sinai Acute GVHD International Consortium (MAGIC) to standardize acute GVHD data collection and curation. We then review the utility of serum biomarkers, specifically the MAGIC Algorithm Probability (MAP) that combines two GI biomarkers (ST2 and REG3α) that has been shown to be more accurate than changes in clinical symptom severity after GVHD treatment. We then present preliminary data on the feasibility of a surrogate clinical trial endpoint that combines clinical response and MAP two weeks after treatment. This novel endpoint is an earlier and potentially better predictor of non-relapse mortality than the current gold standard of clinical response four weeks after treatment. 相似文献
4.
5.
《Transfusion and apheresis science》2022,61(2):103405
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare life-threatening complication of blood transfusion caused by donor T cells that escape rejection by the recipient immune system. These donor T cells drive recipient tissue damage in response to host antigens. On the other hand, GVHD occurring after allogeneic hematopoietic cell transplantation (HCT-GVHD) is also caused by donor T cells, but its pathophysiology is more complex and differs due to the effects of tissue damage caused by pre?HCT conditioning and profound immunosuppression. Both TA-GVHD and HCT-GVHD can be fatal; however, mortality is higher with TA-GVHD due to the paucity of treatment options. Here, we compare and summarize the presentation, diagnosis, pathophysiology, prevention, and treatment of TA-GVHD and HCT-GVHD. 相似文献
6.
7.
《Biology of blood and marrow transplantation》2014,20(8):1089-1103
Chronic graft-versus-host disease (cGVHD) is an autoimmune-like syndrome, and donor B cells play important roles in augmenting its pathogenesis. B cell–depleting anti-CD20 mAb has been administered before or after cGVHD onset for preventing or treating cGVHD in the clinic. Although administration before onset appeared to be more effective, the effect is variable and sometimes minimal. Here, we used 2 mouse cGVHD models to evaluate the preventive and therapeutic effect of anti-CD20 mAb. With the model of DBA/2 donor to MHC-matched BALB/c recipient, 1 intravenous injection of anti-CD20 mAb (40 mg/kg) the following day or on day 7 after hematopoietic cell transplantation when serum autoantibodies were undetectable effectively prevented induction of cGVHD and preserved a strong graft-versus-leukemia (GVL) effect. The separation of GVL effect from GVHD was associated with a significant reduction of donor CD4+ T cell proliferation and expansion and protection of host thymic medullary epithelial cells. Anti-CD20 mAb administration also prevented expansion of donor T cells and induction of cGVHD in another mouse model of C57BL/6 donor to MHC-mismatched BALB/c recipients. In contrast, administration of anti-CD20 mAb after GVHD onset was not able to effectively deplete donor B cells or ameliorate cGVHD in either model. These results indicate that administration of anti-CD20 mAb before signs of cGVHD can prevent induction of autoimmune-like cGVHD while preserving a GVL effect; there is little effect if administered after cGVHD onset. This provides new insights into clinical prevention and therapy of cGVHD with B cell–depleting reagents. 相似文献
8.
Lijie Han Ke Zhao Yuanyuan Li Haohao Han Lizhi Zhou Ping Ma Zhiping Fan Hui Sun Hua Jin Zhongxing Jiang Qifa Liu Jie Peng 《American journal of transplantation》2020,20(4):1014-1027
Although studies have reported that intestinal microbiota are associated with acute graft‐versus‐host disease (aGVHD), they lacked a satisfactory method for predicting aGVHD. We collected stool and blood samples at day 15 posttransplant from 150 patients from two centers who underwent myeloablative conditioning allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Stool microbiota were detected by 16S ribosomal RNA gene sequencing; inflammatory factors and T lymphocytes were detected by multiplex immunoassays and flow cytometry, respectively. A gut microbiota score (GMS) from a LASSO (least absolute shrinkage and selection operator) model was developed and validated to predict aGVHD. In the discovery cohort, the GMS could predict II‐IV aGVHD (area under the receiver operating characteristic [ROC] curve [AUC] = 0.904, P < .0001). Furthermore, the validation model was consistent with the discovery set (AUC = 0.887, P < .0001). Regulatory T/T‐helper 17 (Treg/Th17) cells ratio in the low GMS subgroup was higher compared with the high GMS (P = .012), and the validation set is consistent with the discovery set (P = .003). In addition, high cytokine levels were associated with high GMS. In conclusion, the GMS at neutrophil engraftment could predict aGVHD, and it was a potential and novel method. The GMS was associated with the inflammatory factor and Treg/Th17 balance. 相似文献
9.
Jianwei Zheng Brian Taylor Joseph Dodge Allison Stephans Song Guo Zheng Qiang Chen Xiao Chen 《American journal of transplantation》2020,20(1):64-74
Intestinal graft‐versus‐host disease (GVHD) remains a devastating complication after allogeneic hematopoietic stem cell transplantation (HSCT). Although it has been well established that gut‐tropic donor T cells expressing integrin α4β7 are required to cause intestinal damage, the factors that control the induction of this pathogenic T cell population remain to be identified. Retinoic acid (RA) plays an important role in inducing α4β7 expression on T cells. In this study, we showed that gene expression of retinaldehyde dehydrogenase, the key enzyme involved in RA biosynthesis, is significantly increased in the spleen and mesenteric lymph nodes (MLNs) of irradiated mice. In a C57BL/6‐into‐B6D2F1 allogeneic HSCT model, irradiation significantly increased the induction of α4β7+‐donor T cells in mesenteric lymph nodes and spleen. Furthermore, we found that the RA pathway modulates the ability of dendritic cells to imprint gut‐homing specificity on alloreactive T cells. We also showed that host dendritic cell RA signaling influences GVHD risk. Our studies identified radiation and recipient RA signaling as 2 primary factors that dictate the magnitude of gut‐homing donor T cell induction after allogeneic HSCT. Attenuating radiation‐associated inflammation and modulating host RA signaling represent feasible strategies to mitigate intestinal GVHD by reducing gut‐seeking pathogenic donor T cells. 相似文献
10.
Fevzi F. Yalniz Mohammad H. Murad Stephanie J. Lee Steven Z. Pavletic Nandita Khera Nilay D. Shah Shahrukh K. Hashmi 《Biology of blood and marrow transplantation》2018,24(9):1920-1927
Given the increasing incidence of chronic graft-versus-host disease (cGVHD) and its rapidly escalating costs due to many lines of drug treatments, we aimed to perform a meta-analysis to assess the comparative effectiveness of various treatment options. Using these results, we then conducted a cost-effectiveness analysis for the frequently utilized agents in steroid-refractory cGVHD. We searched for studies examining tacrolimus, sirolimus, rituximab, ruxolitinib, hydroxychloroquine, imatinib, bortezomib, ibrutinib, extracorporeal photopheresis, pomalidomide, and methotrexate. Studies with a median follow-up period shorter than 6 months and enrolling fewer than 5 patients were excluded. Meta-analysis for overall and organ system–specific GVHD response (overall response [ORR], complete response [CR], and partial response [PR]) was conducted for each intervention. Cost per CR and cost per CR?+?PR were calculated as the quotient of the 6-month direct treatment cost by CR and CR?+?PR. Forty-one studies involving 1047 patients were included. CR rates ranged from 7% to 30% with rituximab and methotrexate, respectively, and ORR ranged from 30% to 85% with tacrolimus and ruxolitinib, respectively. Cost per CR ranged from US$1,187,657 with ruxolitinib to US$680 with methotrexate. Cost per ORR ranged from US$453 for methotrexate to US$242,236 for ibrutinib. The most cost-effective strategy was methotrexate for all of the organ systems. Pomalidomide was found to be the least cost-effective treatment for eye, gastrointestinal, fascia/joint, skin, and oral GVHD, and imatinib was found to be the least cost-effective treatment for liver and extracorporeal photopheresis for lung GVHD. We observed huge cost-effectiveness differences among available agents. Attention to economic issues when treating cGVHD is important to recommend how treatments should be sequenced, knowing that many patients will cycle through available agents. 相似文献